Home
Morphotek, Inc.

Morphotek, Inc. Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainmorphotek.com

Year Founded2000

Employees51 - 200

Annual Revenue$25M - $50M

Morphotek, Inc.

Morphotek, Inc. (including company regionals)

morphotek.com

See more website traffic and engagement information

Morphotek, Inc. Revenue up to November 2025 is 25M - 50M

revenue generated by Morphotek, Inc. top domains

Morphotek, Inc. top domains revenue over 3 years

Revenue for Morphotek, Inc. top domains

morphotek.com25M - 50M

See more with Sales Intelligence

Total visits to Morphotek, Inc.'s top domains

Understand Morphotek, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Morphotek, Inc.'s top domains

Analyze Morphotek, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Morphotek, Inc.'s top domains

See how Morphotek, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Morphotek, Inc. top competitors by domain

Top similar sites in November 2025, ranked by their affinity

novartis.comCompany NameNovartisEmployees> 10001HQSwitzerland, BaselAnnual revenue> $1BTotal visits1.4MHealth > Biotechnology and Pharmaceuticals

Top technologies used by Morphotek, Inc.

These are the website technologies, by industry, used by Morphotek, Inc. top domains

Content Management System (5)

Drupal

Conversion & Analytics (4)

Google Analytics

Advertising (3)

Twitter Advertiser

Email Services (3)

Microsoft Exchange Online

More Technologies

7

See all

News & Signals from Morphotek, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMorphotek, Inc. partnered with Rockefeller on Dec 11th '17.Morphotek ®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a Sponsored Research Agreement (SRA) with The Rockefeller University to expand its research efforts around the mechanisms by which the CA125 tumor shed antigen suppresses immune-based therapies.

NewsMorphotek, Inc. launched Antibody Drug Conjugate on Apr 2nd '17.Morphotek®, Inc., a subsidiary of Eisai Inc., announced today the launch of its Antibody Drug Conjugate (ADC) Services business based on its proprietary REsidue-SPEcific Conjugation TechnologyTM (RESPECTTM) and eribulin-linker toxin platforms.

NewsMorphotek, Inc. signed new client Eurofarma Laboratórios S.A on Oct 4th '16.TOKYO, Oct 4, 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that its research subsidiary Morphotek, Inc. has signed an exclusive licensing agreement with Eurofarma Laboratorios S.A. to develop and commercialize the monoclonal antibody farletuzumab (development code: MORAb-003) as a potential anticancer agent in Latin America.